<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956644</url>
  </required_header>
  <id_info>
    <org_study_id>IRBAM_R_04220</org_study_id>
    <nct_id>NCT00956644</nct_id>
  </id_info>
  <brief_title>Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy</brief_title>
  <acronym>I-COMBINE</acronym>
  <official_title>Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To demonstrate that the antihypertensive efficacy of the fixed combination
           irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in
           lowering systolic blood pressure (SBP) as measured by home blood pressure measurement
           (HBPM) after 5 weeks of treatment (W5)

      Secondary Objective:

        -  To compare the antihypertensive efficacy of the fixed combination irbesartan/amlodipine
           150/5 mg with that of amlodipine 5 mg monotherapy after 5 weeks of treatment (W5)

        -  To compare the antihypertensive efficacy of the fixed combination therapy
           irbesartan/amlodipine 150/10 mg with that of amlodipine 10 mg monotherapy at the end of
           treatment (W10)

        -  To examine in each treatment group the change from week 5 to week 10 in SBP and
           diastolic blood pressure (DBP) assessed by HBPM and by office blood pressure measurement
           (OBPM)

        -  To determine the incidence and severity of adverse events
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean home systolic blood pressure</measure>
    <time_frame>At randomisation and week 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean office blood pressure</measure>
    <time_frame>At randomisation, week 5 and week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean home diastolic blood pressure</measure>
    <time_frame>At randomisation, week 5 and week 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>irbesartan/amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irbesartan/amlodipine</intervention_name>
    <description>Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning</description>
    <arm_group_label>irbesartan/amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning</description>
    <arm_group_label>amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Established essential hypertension

          -  Treated with amlodipine 5 mg monotherapy for at least 4 weeks

          -  With uncontrolled BP defined as mean SBP = or &gt; 145 mmHg assessed by OBPM

          -  Signed written inform consent obtained prior to inclusion in the study

        Randomisation Criteria:

          -  Mean SBP = or &gt; 135 mmHg assessed by HBPM

          -  Good compliance with the HBPM protocol defined as at least 12 correct measurements
             performed over the last 6 days of the first period of measurements

          -  Creatinine clearance = or &gt; 30 ml/min, determined by Cockroft formula

        Exclusion criteria:

          -  Mean SBP = or &gt; 180 mm Hg and/or mean DBP = or &gt; 110 mm Hg measured at doctor's office
             at Visit 1

          -  Known or suspected causes of secondary hypertension

          -  Patients with bilateral artery stenosis, renal artery stenosis in a solitary kidney,
             renal transplant or only one functioning kidney

          -  Know contraindications or hypersensitivity to either amlodipine or irbesartan or to
             the combination or history of angioedema related to the administration of an
             angiotensin II receptor antagonist or any combination of the drugs used

          -  Known type 1 diabetes

          -  Know severe hepatic impairment alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) &gt; 5 times the upper limit of normal or history or hepatic
             encephalopathy, esophageal varices, or portocaval shunt

          -  Known severe renal impairment (creatinine clearance &lt; 30 ml/mn)

          -  Concomitant use of any other antihypertensive treatment

          -  Administration of any other investigational drug within 30 days before inclusion

          -  Inability to obtain a valid automatic BP measurement recording

          -  Presence of any severe medical or psychological condition that, in the opinion of the
             investigator, indicate that participation in the study is not in the best interest of
             the patient

          -  Presence of any other conditions (e.g.: geographical, social, etc) that would restrict
             or limit the patient participation for the duration of the study

          -  Pregnant or breast feeding women

          -  Women of childbearing potential unable or unwilling to use an acceptable method to
             avoid pregnancy for the entire study period

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Genes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07602</name>
      <address>
        <city>Campinas</city>
        <zip>13059-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-005</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07605</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07604</name>
      <address>
        <city>São José</city>
        <zip>88103-460</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07601</name>
      <address>
        <city>São Paulo</city>
        <zip>04025-011</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-004</name>
      <address>
        <city>São Paulo</city>
        <zip>04038-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-002</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07603</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 15202</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 15203</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 15204</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 15205</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 15206</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 17003</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 17004</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 17002</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 81803</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 81804</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 81801</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 81802</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 42202</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 42203</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 42204</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 42205</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 42206</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48401</name>
      <address>
        <city>Durango</city>
        <zip>34080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48402</name>
      <address>
        <city>Guadalajara</city>
        <zip>44656</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48403</name>
      <address>
        <city>Guadalajara</city>
        <zip>44656</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48406</name>
      <address>
        <city>Guadalajara</city>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48404</name>
      <address>
        <city>Guadalajara</city>
        <zip>44680</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48405</name>
      <address>
        <city>Mexico</city>
        <zip>06140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48407</name>
      <address>
        <city>Mexico</city>
        <zip>07330</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50401</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50402</name>
      <address>
        <city>Marrakech</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50403</name>
      <address>
        <city>Marrakech</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78804</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78803</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78802</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78801</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 86201</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Egypt</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Tunisia</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Peru</country>
    <country>Saudi Arabia</country>
  </removed_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <last_update_submitted>October 25, 2010</last_update_submitted>
  <last_update_submitted_qc>October 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

